madman
Super Moderator
Medherant transdermal patch development collaboration with Bayer
Coventry, UK (25 March 2024): Medherant Limited (“Medherant”) announces that it has entered into a Development Collaboration Agreement with Bayer for the development of a transdermal patch product for delivery of an already-approved oral medicine. For the last 3 years, Medherant and Bayer have...
Coventry, UK (25 March 2024): Medherant Limited (“Medherant”) announces that it has entered into a Development Collaboration Agreement with Bayer for the development of a transdermal patch product for delivery of an already-approved oral medicine.
For the last 3 years, Medherant and Bayer have worked on formulation development for this product, utilising Medherant’s expertise in the use of laboratory models for assessment of transdermal drug delivery with the TEPI Patch® technology.
The Development and Collaboration Agreement marks the movement of the collaboration to the next phase of development as Medherant and Bayer move the programme to non-clinical studies and approach technology transfer for patch production at Medherant’s contract manufacturing partner. Medherant is responsible for leading the programme through to completion of the clinical proof of concept study.
Following a successful outcome to the clinical proof of concept study, Medherant and Bayer expect to negotiate a definitive licence agreement to enable Bayer to complete the development programme and pursue commercialisation of this novel TEPI Patch transdermal drug delivery product. Medherant anticipates that the licence agreement will provide for payments to Medherant through the development and registration process as well as royalties payable on sales of this product.
Bayer is committed to transforming self-care by offering precision health solutions to enable consumers to better understand and make informed decisions about their own personal health and lifestyle choices.
